One of the first facilities of its kind in the country, we continue to pioneer applications of diagnostic DNA-based testing for:

  • Neoplastic disease
  • Orphan diseases
  • DNA repair disorders
  • Prenatal evaluation

Services:

  • Friedreich ataxia
  • Fusion gene quantitation for disease monitoring in leukemias
  • Oncogene mutation analysis in solid tumors as companion diagnostics for targeted molecular therapies
  • DNA fingerprinting for determination of paternity, twin zygosity and surgical specimen identity
  • Detection of clonal immunoglobulin and T-cell receptor gene rearrangements in lymphomas and leukemias
  • Differentiation of donor from recipient cells after bone marrow or organ transplant by DNA polymorphisms

Orphan Diseases:

Dedicated to disorders too rare to be of interest to general reference laboratories, we offer a way to transfer both the regulatory and workload burdens from the research setting to a licensed clinical laboratory.

  • We provide validated confirmation of mutations identified in research laboratories which can then be reported directly to physicians and patients who request such information for clinical decision-making. This service will be especially beneficial for individuals and families who have been identified as mutation carriers by a research laboratory.
  • We will confirm mutations in a fresh sample (blood, saliva, or cheek swab) from the proband or other known carriers, such as the parents. After a mutation is confirmed, diagnostic, prenatal, and carrier testing is available for other at-risk family members.

DNA Repair Disorders:

Mutation detection, carrier testing and prenatal diagnosis

  • Western Blot for DNA Repair Protein Expression
    • Ataxia Telangiectasia, A-T (ATM)
    • Nijmegen Breakage Syndrome (NBN)
    • A-T-like Disorder (MRE11)
    • NBS-like Disorder (RAD-50)
    • Fanconi Anemia (FANC D1, A, B, C, E, F, G, L and M)
  • Radiation Sensitivity/Colony Survival Assay
  • Rapid Functional Flow Cytometry SMC1 Assay for Ataxia Telangiectasia (A-T) proband and carrier screening

Prenatal Evaluation:

We offer prenatal testing for known familial variants in any gene

  • Assessment of maternal cell contamination
  • Comparison to parental/familial controls
  • Analysis of single base changes as well as some microdeletions previously confirmed in a parent by sequencing
  • Communication with referring physician or genetic counselor

A complete menu of testing for a growing variety of genetic and neoplastic diseases is available upon request.

In addition to our many clinical services, we maintain an active role in basic and applied clinical research.


helix 
Pathologists  helix

Click on the images below to view the pathologists' profiles.


Wayne W. Grody,
M.D., Ph.D., F.A.C.M.G.

Director
 
Richard A. Gatti, M.D.
Co-Director
 
Kingshuk Das, M.D., F.C.A.P.
Associate Medical Director


Joshua Deignan,
Ph.D., F.A.C.M.G.

Associate Technical Director

 


Recent/Featured Publications:

Gau, C.-L., R.A. Rosenblatt, V. Cerullo, F.D. Lay, A.C. Dow, J. Livesay, N. Brunetti-Pierri, B. Lee, S.D. Cederbaum, W.W. Grody and G. Lipshutz. Short-term correction of arginase deficiency in a neonatal murine model with a helper-dependent adenoviral vector. Molec. Ther. 2009; 17: 1155-1163.
Rosove, M.H. and W.W. Grody. Should we be applying warfarin pharmacogenetics to clinical practice? No, not now. . Ann. Intern. Med. 2009; 151: 270-273.
Mumenthaler, S.M., H. Yu, S. Tze, S.D. Cederbaum, A.E. Pegg, D.B. Seligson and W.W. Grody. . Differential expression of arginase II in androgen-dependent versus androgen-independent prostate cancer.. Int. J. Oncol. 2008; 32: 357-365.



Regulatory & HIPAA
| Contact Us | FAQ
© 2010 UCLA Department of Pathology & Laboratory Medicine, All Rights Reserved.